Ikena Oncology, Inc.

NasdaqGM:IKNA Stock Report

Market Cap: US$67.1m

Ikena Oncology Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Mark Manfredi

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage22.2%
CEO tenure6.3yrs
CEO ownershipn/a
Management average tenure1.2yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%

Nov 10
Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%

Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers

Aug 15
Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers

Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues

May 20
Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues

Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?

Apr 29
Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?

We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully

Jan 06
We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully

Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth

Aug 06
Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth

Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts

Mar 23
Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts

Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 21
Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?

Feb 19
Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate

Nov 02
We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate

Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans

Jul 13
Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has Mark Manfredi's remuneration changed compared to Ikena Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$68m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$63m

Mar 31 2023n/an/a

-US$66m

Dec 31 2022US$2mUS$546k

-US$69m

Sep 30 2022n/an/a

-US$52m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$41m

Dec 31 2021US$5mUS$530k

-US$34m

Sep 30 2021n/an/a

-US$63m

Jun 30 2021n/an/a

-US$55m

Mar 31 2021n/an/a

-US$47m

Dec 31 2020US$606kUS$410k

-US$44m

Compensation vs Market: Mark's total compensation ($USD2.46M) is above average for companies of similar size in the US market ($USD662.11K).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.


CEO

Mark Manfredi (52 yo)

6.3yrs

Tenure

US$2,464,255

Compensation

Dr. Mark Manfredi, Ph D., serves as Member of Scientific Advisory Board of Bantam Pharmaceutical, LLC. He has been President, Chief Executive Officer and Director of Ikena Oncology, Inc. since December 201...


Leadership Team

NamePositionTenureCompensationOwnership
Mark Manfredi
President6.3yrsUS$2.46mno data
Jotin Marango
CFO & Head of Corporate Development1.9yrsUS$2.29m0%
$ 0
Bob Lally
Senior Vice President of Finance & Operations1.3yrsno datano data
Srividya Subramanian
VP & Deputy General Counselno datano datano data
Samantha Vuksanic
Head of Human Resources2.8yrsno datano data
Jeffrey Ecsedy
Chief Development Officer2.3yrsno datano data
Navin Parwani
VP & Head of Quality1.2yrsno datano data
David Damphousse
Senior Vice President of Clinical Development Operationsless than a yearno datano data
Caroline Germa
Chief Medical Officerless than a yearno datano data
Valdas Jurkauskas
Senior Vice President of Technical Operationsno datano datano data

1.2yrs

Average Tenure

51yo

Average Age

Experienced Management: IKNA's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Mark Manfredi
President6.3yrsUS$2.46mno data
Jean-Francois Formela
Independent Director8yrsUS$93.49k0.041%
$ 27.2k
George Demetri
Chair of Scientific Advisory Board3.3yrsno datano data
Otello Stampacchia
Independent Director3.3yrsUS$96.49k0.041%
$ 27.2k
Neal Rosen
Member of Scientific Advisory Boardno datano datano data
Kevan Shokat
Member of Scientific Advisory Board3.3yrsno datano data
Owen Hughes
Chairman of the Board1.2yrsUS$71.95kno data
David Bonita
Independent Director8yrsUS$94.99k0.041%
$ 27.2k
Iain Dukes
Independent Director7.3yrsUS$84.99k0%
$ 0
Richard Wooster
Independent Director2.2yrsUS$307.87k0%
$ 0
Josep Tabernero
Member of Scientific Advisory Board3.3yrsno datano data
Maria Koehler
Independent Director2.9yrsUS$80.99k0%
$ 0

3.3yrs

Average Tenure

61.5yo

Average Age

Experienced Board: IKNA's board of directors are considered experienced (3.3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.